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To gain insights into the origin and clinical significance of leukocytes that lack HLA-A allele 
expression due to a copy number neutral loss of heterozygosity in the short arm of chromosome 6 in 
patients with acquired aplastic anemia (AA), we used a high-sensitivity flow cytometry assay to 
investigate the presence of HLA-A allele-lacking leukocytes (HLA-LLs) in 144 AA patients. 
HLA-LLs accounting for 0.2-99.8% of each leukocyte population were detected in 18 of 71 (25.4%) 
newly diagnosed and 25 of 73 (34.2%) previously treated patients. The lineage combination patterns 
of the HLA-LLs in the 43 HLA-LL(+) patients were granulocytes (Gs), monocytes (Ms), B cells 
(Bs), and T cells (Ts; GMBT) in 13 cases, GMB in 16 cases, GM in 11 cases, and B alone in three 
cases. The response rate to anti-thymocyte globulin plus cyclosporine therapy (100%) and the 2-year 
failure-free survival rate (100%) in eight newly diagnosed HLA-LL(+) patients were significantly 
higher than in 23 HLA-LL(-) patients (52.2% for both rates). These data suggest that HLA-LLs are a 
useful marker of the presence of immune pathophysiology in AA and that T-cell attacks against 
hematopoietic progenitor cells, rather than hematopoietic stem cells, can trigger bone marrow failure 
in AA patients. 
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According to the widely-accepted model of acquired aplastic anemia (AA), cytotoxic T lymphocytes 
(CTLs) recognize auto-antigens that are presented on hematopoietic stem cells (HSCs) through their 
class I human leukocyte antigen (HLA) molecules, playing an important role in initiation of the 
autoimmune reactions that lead to bone marrow (BM) failure[1-3]. Several indirect pieces of 
evidence have been reported in previous studies, such as the accumulation of T cells with particular 
clonotypes as demonstrated by T-cell receptor analyses[2, 4, 5], as well as the presence of T-cell 
clones capable of killing myeloid leukemia cell lines within the BM[6, 7]. However, it is entirely 
unknown what kind of cells the antigen-specific T cells attack and how these T cells diminish HSCs 
in vivo.  
Single nucleotide polymorphism (SNP) array analysis reveals the copy number-neutral loss of 
heterozygosity of the HLA haplotype due to uniparental disomy in the short arm of chromosome 6 
(6pLOH) in approximately 13% of AA patients[8-10]. Flow cytometry (FCM) can be substituted for 
SNP array for detection of HLA-A allele-lacking leukocytes (HLA-LLs) as a result of 6pLOH, 
because 6pLOH was revealed in all HLA-LL(+) patients in our previous study[9]. The presence of 
6pLOH is thought to offer compelling evidence of CTL involvement in the development of AA. The 
lack of particular class I HLA alleles that present auto-antigens represents “escape” hematopoiesis 




by 6pLOH(+) HSCs that have survived CTL attack[9]. However, the origin of the HLA-LLs that 
serve as CTL targets and the clinical significance of HLA-LLs in patients with AA have not been 
thoroughly determined, due to the small number of patients analyzed via FCM before 
immunosuppressive therapy in our previous study.  
HLA-LLs can easily be tracked using FCM with monoclonal antibodies (mAbs) specific to 
HLA-A alleles[9]. Studying the lineage diversity of HLA-LLs and the correlation between the 
presence of HLA-LLs and the response to IST may provide insight into the CTL targets responsible 
for the development of AA as well as the clinical significance of HLA-LLs in AA patients. To test 
these hypotheses, we examined a large number of AA patients for the presence of HLA-LLs, and 
determined the lineage combinations and the chronological changes in the HLA-LLs that occurred in 
association with the IST and response to IST in HLA-LL(+) and HLA-LL(-) patients with 
newly-diagnosed AA.  
 
Material and methods 
Patients  
A total of 222 AA patients who were referred to our clinic from October 2006 to November 2013 
were consecutively assessed in this study. Of these, 212 were idiopathic and 10 were 
hepatitis-associated; 113 were assessed pre-treatment and 109 post-treatment; 92 were diagnosed 




with severe AA and 130 with non-severe AA (Table 1). Eighty-four of the 222 patients were 
included in our previous study of 6pLOH using SNP array analysis[9]. Previous treatments included 
rabbit anti-thymocyte globulin (ATG, Thymoglobulin, Sanofi, Paris, France) in 47 patients, 
cyclosporine (CsA) alone in 59 patients, and anabolic steroids alone in three patients. This study 
protocol (No. 287) was approved by the Ethics Committee for Human Genome/Gene Analysis 
Research at Kanazawa University Graduate School of Medical Science, and all patients provided 
their informed consent prior to participation. Severe AA was defined by the presence of a 
hypocellular bone marrow and at least two of three following peripheral blood criteria: absolute 
neutrophil count (ANC) <0.5×109/L, platelet count <20×109/L, and absolute reticulocyte count 
(ARC) <20×109/L[11]. Patients with AA who did not meet criteria for severe AA but with at least 
two of three following peripheral blood criteria: ANC <1.5×109/L, platelet count <50×109/L, and 
ARC <60×109/L, were considered as non-severe AA. ATG at a dose of 2.5 to 3.75 mg/kg per day 
was intravenously administered on day1 to 5. CsA was given 5 mg/kg per day orally, continued for 
at least six months. CsA was started on day-7 or day1 in the combination with ATG. Responses to 
IST were evaluated according to established criteria[12] after six months of treatment, and patients 
who achieved complete or partial responses were considered to be responders.  
Flow cytometry 
Ethylenediaminetetraacetic acid-added peripheral blood (PB) was collected from participating 




patients at diagnosis and/or after treatment. HLA-A allele expression on granulocytes (Gs), 
monocytes (Ms), B cells (Bs), T cells (Ts), and NK cells was analyzed by FCM using a FACSCanto 
II (Becton Dickinson, Franklin Lakes, NJ, USA) with the FlowJo program (Tree Star, Inc., Ashland, 
OR, USA). This study used mAbs specific for HLA-A24, A2, A26, A31, as well as the lineage 
marker antibodies specific for CD11b in Gs, CD33 in Ms, CD19 in Bs, CD3 in Ts, and NKp46 in 
NK cells. For patients in whom HLA-A alleles had not been determined, PB mononuclear cells 
(PBMCs) were cryopreserved, and thawed Ms were later subjected to FCM after HLA-A allele data 
became available. When HLA-LLs were detected in patients who were heterozygous with either 
HLA-A*33:03, A*01:01, or A*03:01 and either HLA-A24, A2, A26, or A31, positive results were 
confirmed by examining a second sample from the same patient. HLA-LLs were not assessable in 
patients who were homozygous for the HLA-A allele by this FCM assay because 6pLOH does not 
change the HLA-A allele expression pattern in these patients.  
Measurement of GPI-AP- Gs was performed as previously described[13], with minor 
modifications. The presence of ≥0.003% fluorescein-labeled proaerolysin (FLAER)–CD11b+ or 
CD55–CD59–CD11b+ Gs was defined as an abnormal increase, based on results obtained from 187 
healthy individuals[13]. The mAbs used for this study are detailed in Supplementary Table E1.  
Analysis of genomic copy numbers and detection of 6pLOH  




DNA extracted from whole blood and sorted G populations was subjected to genomic and 
allele-specific copy number analyses using GeneChip® 250K arrays (Affymetrix, Inc., Santa Clara, 
CA, USA), as previously described[14, 15]. GPI-AP+ and GPI-AP- cells were sorted from G 
samples obtained from patients possessing both HLA-LLs and GPI-APs- cells using FACSAria II 
(Becton Dickinson, Franklin Lakes, NJ, USA).  
HLA-A and HLA-B gene analysis using a next generation sequencer 
Genomic abnormalities responsible for the failure of class I allelic expression by isolated Bs were 
analyzed using a next generation Roche GS Junior System benchtop sequencer (Roche, Basel, 
Switzerland), as previously described[16].  
Statistical Analysis 
Data obtained from both treated and untreated patients were used to characterize HLA-LLs while 
only the data from untreated patients were used for analyzing the influence of HLA-LLs on 
responses to IST and prognosis of AA. All the data are reported as the mean ± S.E. of triplicate 
experiments. The results were analyzed using Fisher’s exact test and the log-rank test. P-values of 
<0.05 were considered to indicate statistical significance. Failure-free survival was defined as the 
time from the first day of ATG therapy until a relapse of pancytopenia, stem cell transplantation, 
progression to myelodysplastic syndromes (MDS)/acute myeloid leukemia or disease-related death. 
Overall survival was defined as the time from the first day of ATG therapy until death. All statistical 




analyses were performed using EZR, a graphical user interface for R 2.13.2 (R Foundation for 
Statistical Computing, Vienna, Austria)[17]. 
 
Results 
Prevalence of HLA-LLs 
A total of 144 (64.9%) patients were heterozygous for the HLA-A allele, and were therefore able to 
be assessed for the presence of HLA-LLs by FCM. The sensitivity of FCM in detecting HLA-LLs 
differed among the four anti-HLA-A allele-specific mAbs. Mixing experiments that used blood 
samples containing >90% A24 lacking (A*24:02, A*24:04, and A*24:20) or >90% A2 lacking 
(A*02:01, A*02:06, and A*02:07) Gs as well as normal blood samples showed FCM using 
fluorescence-labeled specific mAbs for these alleles to detect >0.5% of Gs that lacked either of the A 
alleles. The sensitivities of FCM using anti-A26 and anti-A31 antibodies (Abs), in combination with 
fluorescence-labeled anti-mouse IgM Abs, were 5% and 15%, respectively (data not shown). 
Eighteen (25.4%; 10 with severe AA and eight with non-severe AA) of the 71 pre-treatment patients, 
and 25 (34.2%; 12 with severe AA and 13 with non-severe AA) of the 73 post-treatment patients 
were found to be positive for HLA-LLs. The median percentages in each lineage were 34.7% 
(0.8-99.4%, n=40) for Gs; 34.3% (0.6-99.8%, n=40) for Ms; 10% (0.5-94.8%, n=32) for Bs; and 2% 
(0.2-21.8%, n=13) Ts (Fig. 1A, B).  




Lineage diversity of HLA-LLs 
The lineage combinations of HLA-LLs in the 43 HLA-LL(+) patients were GMBT in 13, GMB in 
16, and GM in 11 (Fig. 1A, Table 2, and Supplementary Table E2). Unexpectedly, HLA-LLs were 
found in Bs alone in three patients (Fig. 1A, C). The presence of 6pLOH was confirmed via deep 
sequencing of isolated Bs from one of these three patients (Case 43, Supplementary Table E3). 
Two of the three patients (Cases 41, 42) showed complete responses at the time of sampling three 
years after ATG therapy and 20 years after CsA therapy, while Case 43 required low-dose CsA to 
maintain good hematopoietic function.   
Blood samples from 23 of the 43 HLA-LL(+) patients were obtained for follow-up at 1-40 
months after initial analysis. HLA-LLs remained detectable in all but one patient (Case 35) with the 
GMB pattern, in whom HLA-lacking Gs decreased from 11.7% before treatment to 0% after 12 
months of ATG therapy (Fig. 2A). In the other 22 patients, including two newly-diagnosed patients 
whose samples were available once they achieved remission through IST, clone sizes and lineage 
combination patterns of HLA-LLs were not observed to change during the follow-up period (Fig. 
2B).  
Table 2 summarizes characteristics of the 43 patients who possessed HLA-LLs. The clone sizes 
of HLA-LLs in each leukocyte lineage were consistently G≒M≥B>T. The percentages of Ms 
lacking HLA-A allele expression (HLA-LMs) in cryopreserved PBMCs obtained at diagnosis were 




compared with those of freshly obtained PBMCs from two patients after HLA-A alleles were 
determined. There were no differences in the clone sizes of HLA-LMs between the two sets of 
samples (1.1% v. 1.0%, and 44.7% v. 48.3%).  
HLA-LLs in patients possessing GPI-AP- cells 
An increase in the percentage of GPI-AP- Gs, ranging from 0.003% to 99.4%, was detected in 103 of 
the 144 participating patients whose samples were available for the analyses of GPI-AP- cells. 
Twenty-five (24.3%) of the103 patients with increased GPI-AP- Gs (paroxysmal nocturnal 
hemoglobinuria (PNH+) patients), and 18 (43.9%) of the 41 patients without these aberrant cells 
(PNH- patients) possessed HLA-LLs (P=0.026). Among the 25 PNH+ patients, Gs lacking HLA-A 
allele expression (HLA-LGs) were detected in both GPI-AP+ and GPI-AP- cells in three patients, 
while HLA-LGs were only detected in GPI-AP+ cells in the other 22 patients (Fig. 3).  
Response to IST and survival in patients with and without HLA-LLs 
A total of 50 patients, including eight HLA-LL(+) patients, 23 HLA-LL(-) patients, and 19 patients 
who were homozygous for the HLA-A allele, underwent IST including ATG plus CsA after blood 
samples were obtained for FCM. All eight HLA-LL(+) patients, as well as 12 (52.2%) HLA-LL(-) 
patients (P=0.033), and 12 (63.2%) homozygous patients responded to treatment (Table 3A and Fig. 
4A). Of the 47 patients who had already been treated with IST at the time of sampling, 45 including 
nine HLA-LL(+), 17 HLA-LL(-), and 19 homozygous patients were evaluable for responses to IST 




and two patients were lost to follow up. The rate of response to IST among the nine HLA-LL(+) 
patients was only slightly higher than that among the 17 HLA-LL(-) patients (66.7% vs. 58.8%; 
P=1.0, Table 3B). The prevalence of increased of GPI-AP- cell numbers, which is known to be 
associated with a good response to IST, was significantly lower in the HLA-LL(+) patients than in 
the HLA-LL(-) patients (33.3% vs. 76.5%; P=0.046). The response rate among homozygous patients 
(68.4%) was comparable to the response rates of the other two groups. 
The median follow-up period was 817.5 days (range, 11 to 1584 days). The two-year failure-free 
survival rate (100%) in the previously untreated HLA-LL(+) patients were significantly higher than 
that of the HLA-LL(-) patients (52.2%, P=0.018) and that of the patients who were homozygous for 
the HLA-A allele (63.2%, P=0.022); however, there were no significant differences in the overall 
survival rates of the three groups (Fig. 4B, C). 
 
Discussion 
Our previous study used a SNP array analysis to reveal that approximately 13% of AA patients had 
6pLOH(+) cells[9, 10]. However, the involvement of the lineage of HLA-LLs in 6pLOH(+) patients 
remained unclear due to the limited number of patients whose leukocytes were analyzed with FCM. 
The current study, in which a large number of AA patients were analyzed using anti-HLA-A allele 
specific mAbs, revealed several new aspects of HLA-LLs. First, the prevalence of HLA-LLs in 




evaluable patients with newly diagnosed AA (25.4%) was higher than the prevalence of 6pLOH 
(15%) in newly diagnosed patents in our previous study[9]. The higher prevalence of HLA-LLs can 
be explained by FCM’s greater sensitivity in the detection of aberrant cells (in comparison to the 
SNP array in the detection of 6pLOH(+) leukocytes). Another explanation is that in some patients, 
HLA-LLs can be caused by mechanisms other than 6pLOH. It has been shown that mutations in the 
coding region of class I HLA alleles have the potential to produce HLA-LLs in patients with AA[18, 
19]. Some of the HLA-LLs observed in patients from the current study may have been produced by 
mutations of the coding region of HLA-A alleles. Given the fact that the presence of HLA-LLs 
cannot be evaluated in one third of AA patients (due to HLA-A homogeneity or the lack of mAbs 
specific to HLA-A1 and A33, as well as other HLA class I alleles, including HLA-B and HLA-C), 
the true incidence of HLA-class I allele-lacking leukocytes in newly-diagnosed AA patients may be 
higher than 25.4%. 
Our previous study showed that all 11 patients with newly diagnosed 6pLOH(+) AA responded to 
either ATG plus CsA or CsA alone while the response rate to IST in 6pLOH(-) AA patients was 73%. 
The current study which involved a new cohort of HLA-LL(+) patients, including eight newly 
diagnosed AA patients also showed a 100% response rate to ATG, which was significantly higher 
than the response rate (52.2%) in HLA-LL(-) AA patients. The remarkably high response rate to IST 
and the significantly higher two-year failure-free survival rates of HLA-LL(+) patients in 




comparison to HLA-LL(-) patients support the hypothesis that the presence of HLA-LLs is strongly 
associated with the CTL-mediated immune pathophysiology of AA. In agreement with this 
hypothesis, 6pLOH has been rarely detected in patients with inherited BM failure[20] or in patients 
with myelodysplastic syndromes[21] where the CTL-mediated immune mechanisms are not 
involved in the BM failure. These scenarios are further supported by the recent reports showing that 
the 6pLOH provides a common mechanism of leukemic relapse after HLA haploidentical stem cell 
transplantations, in which leukemic cells that lost the mismatched HLA haplotype through 6pLOH 
are thought to escape the immunologic surveillance of the engrafted donor T cells[22, 23]. Indeed, 
we successfully isolated a T-cell clone that was capable of killing hematopoietic cells in an 
HLA-B*40:02-restricted manner from one of the 6pLOH(+) patients (case 8)[7]. On the other hand, 
a recent analysis of 256 severe AA patients, including 33 6pLOH(+) patients, who were treated with 
horse ATG in the United States failed to show a better response rate in comparison to 6pLOH(-) 
patients[10]. Another recent study by Betensky et al. detected 6pLOH in eight (11.3%) of 71 patients 
with bone marrow failure using a SNP array analysis and found no significant difference in the 
response rate to IST between 6pLOH(+) patients and 6pLOH(-) patients (50% v. 77.8%)[24]. The 
lower response rate to IST in the two studies from the USA than ours may be attributed to the lower 
sensitivity of the SNP array analysis in comparison to FCM in the detection 6pLOH(+) leukocytes, 
which could underestimate the prevalence of 6pLOH(+) patients. The differences in the patients’ age 




may also have affected the response to IST. Our study included only 6% pediatric patients while 
76.1% of the patients studied by Betensky et al. were children younger than 21 years old. The 
prognostic value of 6pLOH(+) leukocytes must be examined by prospective studies which include a 
greater number of AA patients. 
One of the important finding of the current study is the diversity in the lineage of HLA-LLs 
within individual patients with AA. In contrast to our previous study, which revealed 6pLOH(+) cells 
in all lineages of leukocytes, many patients with HLA-LGs and HLA-LMs did not show HLA-LLs 
in lymphocytes. The same restricted patterns of lineage combination were observed to remain 
unchanged for one to 16 months in patients with newly diagnosed AA, a finding compatible with a 
single cell origin of the HLA-LLs. These findings suggest that the hematopoietic precursor clones 
that escape CTL attack are hematopoietic progenitor cells (HPCs) that lack the capacity to 
differentiate into lymphoid cells but are capable of self-renewing to support myelopoiesis for long 
periods of time. Sun et al. recently demonstrated that murine hematopoiesis is supported by a limited 
number of HPCs rather than HSCs[25]. We previously demonstrated that in AA patients who possess 
GPI-AP- cells, self-renewing PIGA-mutant HPCs with limited differentiation capacity produce 
GPI-AP- cells for many years, in a similar manner to 6pLOH(+) HPCs[26]. Unlike PIGA-mutant 
HPCs lacking all GPI-APs, many of which potentially play important roles in the regulation of 
hematopoiesis, 6pLOH(+) HPCs are very similar to normal HPCs. These in vivo observations 




suggest that hematopoiesis in humans may be supported, at least in part, by HPCs. 
 The presence of “escape” hematopoiesis by HPCs with limited differentiation capacity provides 
insight into the pathogenesis of AA. In Cases 14-29, which possessed HLA-LLs in GMB, CTL 
targets are presumed to be HPCs capable of differentiating into GMB (Supplementary Table E2). 
The depletion of HPCs by specific CTLs, however, does not itself lead to BM failure because other 
HSCs that do not share antigens with the target HPCs compensate for the HPC loss by replenishing 
new HPCs. It is even more difficult to relate the presence of HLA-LLs in the three cases in which 
they were observed in Bs alone to the pathogenesis of BM failure, because CTLs are thought to 
target Bs or B precursors. All three of these patients had normal serum immunoglobulin levels and 
showed good responses to IST before sampling. A plausible mechanism for BM failure is indirect 
injury to BM precursors by cytokines produced by CTLs that respond to antigen-presenting B 
precursors or HPCs. Our previous study indicated that non-specific suppression of hematopoiesis by 
cytokines, rather than a decrease in the number of HSCs induced by CTLs, was the major 
mechanism of immune-mediated BM failure[9]. The current chronological studies of 
newly-diagnosed AA patients who are responsive to IST also show the persistence of HLA-LLs after 
successful IST at similar percentages to those observed before IST. The bystander effect has been 
suggested to influence BM failure caused by the immune response to abnormal HSCs with trisomy 8 
by a previous study on AA patients with trisomy 8[27]. These findings suggest that CTLs specific for 




HPCs can trigger BM failure, but may not play a major role in the development of AA.  
In conclusion, this study revealed HLA-LLs in approximately one fourth of newly diagnosed AA 
patients. Considering the markedly high FFS rate and the response rate to IST in HLA-LL(+) 
patients, all AA patients should be screened for the presence of HLA-LLs in order to select an 
optimal therapy.  
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Table 1. Patient characteristics 
All Untreated Treated
(n=222) (n=113) (n=109)
Median age,  years (range) 60 (2-93) 62 (16-91) 59 (2-93)
Sex, male /female 108/114 49/64 59/50
Diagnosis
     Idiopatic AA 212 109 103
     Hepatitis-asociated AA 10 4 6
Severity
     Severe 92 36 56
     Non-severe 130 77 53
Patients with increased GPI-AP- cells 158 (71.2%) 84 (74.3%) 74 (67.9%)
Patients heterozygous for HLA-A allele 144 (64.9%) 71 (62.8%) 73 (67.0%)
Abbreviations: AA, aplastic anemia; GPI-AP- cells, glycosylphosphatidylinositol-anchored protein




















Table 2. Characteristics of patients with HLA-LLs 
Patients with HLA-LLs
Cases (n) 43
Median age,  years (range) 55 (18-93)
Sex, male/female 24/19
Diagnosis
     Idiopatic AA 40
     Hepatitis-asociated AA 3
Severity
     Severe 22
     Non-severe 21
Patients with increased GPI-AP- cells 25 (58.1%)
Untreated/Treated 18/25
Lineage combination of HLA-LLs
     GMBT 13 (30.2%)
     GMB 16 (37.2%)
     GM 11 (25.6%)
     B 3 (7.0%)
Missing HLA-A allele
     HLA-A2 28 (65.1%)
     HLA-A24 5 (11.6%)
     HLA-A26 3 (7.0%)
     HLA-A31 7 (16.3%)
Abbreviations: AA, aplastic anemia; GPI-AP- cells,
glycosylphosphatidylinositol-anchored protein deficient cells; HLA-LLs,
HLA-A allele-lacking leukocytes; G, granulocyte; M, monocyte; B, B cell;
T, T cell.  
 









Number of patients evaluable for response to ATG plus CsA (n) 50 8 23 19
Median age,  years (range) 55 (16-77) 48 (30-68) 55 (16-77) 57 (20-75)
Sex, male/female 25/25 2/6 12/11 11/8
Severity
     Severe 25 6 11 8
     Non-severe 25 2 12 11





Number of patients evaluable for response to ATG plus CsA (n) 45 9 17 19
Median age,  years (range) 55 (2-81) 54 (22-69) 50 (2-77) 59 (25-81)
Sex, male/female 25/20 8/1 5/12 12/7
Severity
     Severe 32 6 12 14
     Non-severe 13 3 5 5
Number of patients who achieved response (n) 29 (64.4%) 6 (66.7%) 10 (58.8%) 13 (68.4%)
Abbreviations: ATG, anti-thymocyte globulin; CsA, cyclosporine; HLA-LLs, HLA-A allele-lacking leukocytes.
* Responses to immunosuppressive therapy were evaluated according to the Camitta criteria after 6 months of treatment. Patients who achieved
complete or partial response were considered responders.
Untreated
Treated






Figure 1. HLA-A allele-lacking leukocytes (HLA-LLs) in patients with aplastic anemia (AA) 
A. The HLA-LLs of four cases that possessed HLA-LLs in granulocytes (Gs), monocytes (Ms), B 
cells (Bs), and T cells (Ts) were GMBT (Case 8), GMB (Case 19), GM (Case 37), and B alone (Case 
41) are shown. Histograms shown in the red rectangles represent positive results on HLA-LLs. B. 
Scattergrams and histograms are shown for a representative case (Case 14) that possessed minor 
(0.8%) HLA-A24-lacking populations in GMB. No HLA-A2-lacking cells were detected in this case. 
C. Histograms of three cases who possessed HLA-LLs in Bs alone are shown.  
 
Figure 2. Chronological changes in HLA-A allele-lacking leukocytes (HLA-LLs) of associated 
with immunosuppressive therapy 
A. Changes in HLA-A allele-lacking granulocytes (HLA-LGs) in three cases are shown. All three 
cases responded to anti-thymocyte globulin (ATG) plus cyclosporine, and achieved partial response 
after 12 months of therapy. The percentages of HLA-LGs remained unchanged in all cases except 
Case 35. Enlarged figures of HLA-LGs are shown in red rectangles. B. The percentages of HLA-LLs 
in the leukocyte lineages of individual HLA-LL(+) patients, as determined at two different time 
points (1 and 2), are exhibited according to lineage combination patterns. The second samples were 
obtained 1-40 months after examination of initial samples.  
 
Figure 3. HLA-A allele-lacking leukocytes (HLA-LLs) in 
glycosylphosphatidylinositol-anchored protein containing (GPI-AP+) and 
glycosylphosphatidylinositol-anchored protein deficient (GPI-AP-) granulocyte populations 
A. The GPI-AP+ and GPI-AP- granulocytes of two patients possessing HLA-LLs in the GPI-AP+ 
population alone (Case 8) and in both the GPI-AP+ and GPI-AP- populations (Case 19) were sorted 
and subjected to single nucleotide polymorphism (SNP) array analysis. The double lines compatible 
with 6pLOH were seen only in DNA derived from the GPI-AP+ population of Case 8, while the 




double lines were evident in both DNA samples derived from GPI-AP+ and GPI-AP- populations of 
Case 19. B. HLA-LLs in different lineages of GPI-AP+ and GPI-AP- cells of the three cases who 
possessed GPI-AP-HLA-LLs are shown. Histograms shown in the red rectangles represent positive 
results for HLA-LLs.  
 
Figure 4. Response to immunosuppressive therapy (IST) and the prognosis after IST in 
untreated patients with/without HLA-A allele-lacking leukocytes (HLA-LLs), and in untreated 
patients homozygous for the HLA-A allele 
A. The IST response rate of three untreated groups. The response rate of HLA-LL(+) patients was 
significantly higher than that of HLA-LL(-) patients (100% vs. 52.2%; P=0.033). B and C. The 
overall survival and failure-free survival (FFS) in HLA-LL(+) patients, HLA-LL(-) patients and 
patients homozygous for the HLA-A allele. The FFS rate in HLA-LL(+) patients was significantly 
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Supplementary Table E1.  Antibodies used in flow cytometry 
Surface Antigen  Isotype  Fluorescein  Source  
CD3  IgG1  PerCP-Cy5.5  BD Biosciences  
CD11b  IgG1  PE  BD Biosciences  
CD11b  IgG1  APC  Beckman Coulter  
CD19  IgG1  APC-Cy7  Beckman Coulter  
CD33  IgG1  APC  Beckman Coulter  
NKp46 IgG1  PE  Beckman Coulter  
CD55 IgG2a  FITC  BD Biosciences  
CD55 IgG2a  PE BD Biosciences  
CD59 IgG2a  FITC BD Biosciences  
CD59 IgG2a  PE BD Biosciences  
FLAER -  Alex Fluor 488 Pinewood Scientific Services 
HLA-A2/28  IgG2a  FITC  ONE LAMBDA  
HLA-A9/24  IgG2b  FITC  ONE LAMBDA  
HLA-A11  IgM  Biotine  ONE LAMBDA  
HLA-A25/26  IgM  Biotine  ONE LAMBDA  
HLA-A30/31  IgM  Biotine  ONE LAMBDA  
Streptavidin  -  PE  BD Biosciences  
Abbreviations: PerCP-Cy5.5, PerCP-Cy5.5 Tandem; PE, phycoerthrin; APC, Allophycocyanin; APC-Cy7,  
Allophycocyanin-Cy7 Tandem; FITC, fluorescein isothiocyanate. 















Clone size of       
HLA-LLs (%) 
Lineage combination               
of HLA-LLs 
Size of granulocytes that have both GPI-AP- 
and HLA-LL(+) phenotype (%) 
1  84  F NSAA UT - 24 3.8  GMBT NA 
2  52  M NSAA T 12.3 2 8.4  GMBT 2.7 
3  54  M SAA T - 2 11.5  GMBT NA 
4  57  F SAA UT 1.9  24 12.0  GMBT NA 
5  38  M NSAA UT - 2 14.8  GMBT NA 
6  82  M NSAA T - 2 16.3  GMBT NA 
7  62  M NSAA T 41.6  26 29.6  GMBT NA 
8  22  M NSAA T 1.1  24 50.3  GMBT NA 
9  39  M SAA T - 2 54.2  GMBT NA 
10  18  M NSAA T 0.6  26 56.5  GMBT NA 
11  50  M NSAA UT 0.06  2 69.7  GMBT NA 
12  25  F NSAA T 1.05  2 95.4  GMBT 21.1 
13  45  M NSAA T - 2 99.8  GMBT NA 
14  68  F SAA UT 14.2  2 0.8  GMB NA 
15  69  M SAA T 4.9  2 1.5  GMB NA 
16  39  F SAA UT 4.3  2 2.0  GMB NA 
17  72  F NSAA T - 2 10.5  GMB NA 
18  39  F NSAA UT 2.6  2 23.2  GMB NA 
19  42  M NSAA T 0.3  2 31.4  GMB 93.6 
20  64  F SAA T - 2 48.6  GMB NA 
21  63  M NSAA T 2.7  2 61.5  GMB NA 
22  51  F NSAA UT - 2 86.8  GMB NA 
23  53  M SAA T - 2 88.4  GMB NA 
24  59  M SAA T 2.6  31 92.5  GMB NA 
25  74  F NSAA T 0.1  31 97.1  GMB NA 
26  69  M SAA T - 31 98.0  GMB NA 
27  79  M SAA UT - 2 98.3  GMB NA 
28  42  M SAA T 0.2  31 98.6  GMB NA 
29  93  F NSAA T 0.0  31 99.0  GMB NA 
30  85  F NSAA UT 0.0  2 1.2  GM NA 




Abbreviations: M, male; F, female; SAA, severe aplastic anemia; NSAA, non-severe aplastic anemia; GPI-AP- cells, glycosylphosphatidylinositol-anchored protein deficient 
cells; UT, untreated; T, treated; HLA-LLs, HLA-A allele-lacking leukocytes; G, granulocyte; M, monocyte; B, B cell; T, T cell; NA, not applicable.  
* Severity were evaluated according to the Camitta criteria.  















31  77  F SAA UT 0.0  2 1.4  GM NA 
32  73  F SAA UT 4.3  2 3.5  GM NA 
33  30  F NSAA UT 24.0  2 5.2  GM NA 
34  45  F SAA UT 3.2  2 6.0  GM NA 
35  55  F SAA UT 0.4  2 14.4  GM NA 
36  33  M SAA UT - 2 31.8  GM NA 
37  25  M NSAA UT - 24 38.9  GM NA 
38  74  M SAA UT 0.02  24 61.1  GM NA 
39  66  F SAA T - 2 89.8  GM NA 
40  53  M SAA T - 31 92.0  GM NA 
41  23  M NSAA T - 26 4.4  B NA 
42  61  M SAA T - 2 12.2  B NA 
43  76  F SAA T 0.02  31 13.2  B NA 




Supplementary Table E3. Comparison of read depth between HLA-A31 positive and negative cells in case 4 
                                                     
A) HLA-A31(+) cells
Minimum Maximum Average observed corrected
A*24:02:01:01 28 1055 542 0.95 1.00
A*31:01:02 45 888 571
B*40:02:01 114 1506 665 0.71 1.00
B*52:01:01:02 256 1596 932
B) HLA-A31(-) cells
Minimum Maximum Average observed corrected
A*24:02:01:01 15 551 346 0.44 0.46
A*31:01:02 9 230 152
B*40:02:01 12 504 134 0.32 0.45
B*52:01:01:02 81 676 424
Read depth  Average depth ratio
Read depth Average depth ratio
                                                                                                                                                                
 
 
